Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Clayton Ellison

Physician Assistant Glenwood, AR Physician Assistant

NPI 1295956316 CMS profile 769865

234 E Broadway, Glenwood, AR 71943

Open in the dashboard

General payments

$287

7 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clayton Ellison of Glenwood, AR is reported in the CMS Open Payments database as having received $287 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $137 3
2024 General $18 1
2023 General $118 2
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clayton Ellison
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Clayton Ellison were reported at $137. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Clayton Ellison Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $15 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $118 $167 $52–$557 $160
2024 $18 $178 $55–$600 $164
2025 $137 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $100 1 payment
  2. Takeda Pharmaceuticals U.S.A., Inc. $96 1 payment
  3. Novo Nordisk Inc $35 2 payments
  4. AbbVie, Inc. $23 1 payment
  5. Ortho-Clinical Diagnostics, Inc. $18 1 payment
  6. Abbott Laboratories $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $287 7 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $100 1 payment
  2. HYQVIA $96 1 payment
  3. Ozempic $35 2 payments
  4. VRAYLAR $23 1 payment
  5. Sofia $18 1 payment
  6. RYBELSUS $18 1 payment
  7. Proclaim IPG $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

5,543

Median for Physician Assistant: 241

Drug cost

$559,834

Median for Physician Assistant: $4,110

Branded share of claims

23.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 148 $178,911
Mounjaro Tirzepatide Brand 108 $139,683
Eliquis Apixaban Brand 57 $57,947
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $38,567
Breo Ellipta Fluticasone/Vilanterol Brand 33 $19,108
Xarelto Rivaroxaban Brand 13 $17,678
Farxiga Dapagliflozin Propanediol Brand 11 $12,960
Myrbetriq Mirabegron Brand 12 $8,503
Symbicort Budesonide/Formoterol Fumarate Brand 13 $6,107
Vascepa Icosapent Ethyl Brand 15 $5,385

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$107,677

Of which drugs: $826

Medicare patients

583

Average age 73

Services billed

2,262

299 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 43%
Diabetes 33%
Chronic kidney disease 32%
COPD 28%
Depression 23%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 28 72 $327
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 38 156 $105
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 44 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record